Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 1, 2012, Pages 27-35

  Hermans, Kris ^a   Van Den Plas, Dave ^a   Everaert, Arnout ^a   Weyenberg, Wim ^a   Ludwig, Annick ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Chitosan; Cyclosporine A; Factorial design; Nanoparticles; PLGA

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHITOSAN; CONCANAVALIN A; CYCLOSPORIN A; EUDRAGIT RS; INTERLEUKIN 2; NANOPARTICLE; POLYGLACTIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DISPERSION; DRUG ABSORPTION; DRUG RELEASE; DRUG TOLERABILITY; EMULSION; EVAPORATION; FACTORIAL DESIGN; HUMAN; HUMAN CELL; IN VITRO STUDY; LACRIMAL FLUID; LEUKEMIA CELL LINE; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; STATIC ELECTRICITY; ZETA POTENTIAL;

ANIMALS; CATIONS; CHITOSAN; CYCLOSPORINE; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; EPITHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LACTIC ACID; MUCUS; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLVENTS; STATIC ELECTRICITY; SWINE; TEARS;

EID: 84866021356     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.05.003     Document Type: Article

References (32)

1. E. Donnenfeld, and S.C. Pflugfelder Topical ophthalmic cyclosporine: pharmacology and clinical uses Surv. Ophthalmol. 54 2009 321 338
2. S.C. Pflugfelder Antiinflammatory therapy for dry eye Am. J. Ophthalmol. 137 2004 337 342
3. P.C. Waldmeier, K. Zimmermann, T. Qian, M. Tintelnot-Blomley, and J.J. Lemasters Cyclophilin D as a drug target Curr. Med. Chem. 10 2003 1485 1506
4. B. Strong, W. Farley, M.E. Stern, and S.C. Pflugfelder Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca Cornea 24 2005 80 85
5. V.H.L. Lee, and J.R. Robinson Topical ocular drug delivery: recent developments and future challenges J. Ocul. Pharmacol. 2 1986 67 108
6. A. Ludwig The use of mucoadhesive polymers in ocular drug delivery Adv. Drug Del. Rev. 57 2005 1595 1639
7. F. Lallemand, O. Felt-Baeyens, K. Besseghir, F. Behar-Cohen, and R. Gurny Cyclosporine A delivery to the eye: a pharmaceutical challenge Eur. J. Pharm. Biopharm. 56 2003 307 318
8. J.K. Milani, U. Pleyer, A. Dukes, H.J. Chou, S. Lutz, D. Ruckert, K.H. Schmidt, and B.J. Mondino Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye Ophthalmology 100 1993 890 896
9. P. Calvo, A. Sanchez, J. Martinez, M.I. Lopez, M. Calonge, J.C. Pastor, and M.J. Alonso Polyester nanocapsules as new topical ocular delivery system for cyclosporin A Pharm. Res. 13 1996 311 315
10. A.M. De Campos, A. Sánchez, and M.J. Alonso Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporine A Int. J. Pharm. 224 2001 159 168
11. S.L. Law, K.J. Huang, and C.H. Chiang Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption J. Control. Release 100 2000 135 140
12. M.J. Alonso, and A. Sánchez The potential of chitosan in ocular drug delivery J. Pharm. Pharmacol. 55 2003 1451 1463
13. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi Eudragit® RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen Eur. J. Pharm. Sci. 16 2002 53 61
14. C. Bucolo, A. Maltese, F. Maugeri, B. Busa, G. Puglisi, and R. Pignatello Eudragit® RL100 nanoparticle system for the ophthalmic delivery of cloricromene J. Pharm. Pharmacol. 56 2004 841 846
15. K. Dillen, J. Vandervoort, G. Van den Mooter, L. Verheyden, and A. Ludwig Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles Int. J. Pharm. 314 2006 72 82
16. K. Dillen, S. Bozdag, J. Vandervoort, and A. Ludwig Evaluation of the physicochemical characteristics and activity of various kinds of ciprofloxacin HCl-loaded cationic nanoparticles J. Drug Deliv. Sci. Technol. 17 2007 49 56
17. J. Vandervoort, K. Yoncheva, and A. Ludwig Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles Chem. Pharm. Bull. 52 2004 1273 1279
18. P. Calvo, M. Alonso, J. Vila-Jato, and J. Robinson Improved ocular bioavailability of indomethacin by novel ocular drug carriers J. Pharm. Pharmacol. 48 1996 1147 1152
19. A. Mühlen, C. Schwartz, and W. Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism Eur. J. Pharm. Biopharm. 45 1998 149 155
20. A. Zimmer, J. Kreuter, and J. Robinson Studies on the transport pathway of PBCA nanoparticles in ocular tissues J. Microencapsul. 8 1991 497 504
21. K. Yoncheva, J. Vandervoort, and A. Ludwig Influence of chitosan coating layer on the properties of surface modified poly (lactide-co-glycolide) nanoparticles J. Dispers. Sci. Technol. 30 2009 213 216
22. K. Dillen, W. Weyenberg, J. Vandervoort, and A. Ludwig The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanaoparticles Eur. J. Pharm. Biopharm. 58 2004 539 549
23. J.W. Loh, G. Yeoh, M. Saunders, and L.Y. Lim Uptake and cytotoxicity of chitosan nanoparticles in human liver cells Toxicol. Appl. Pharmacol. 249 2010 148 157
24. L.F. Qi, Z.R. Xu, Y. Li, X. Jiang, and X.Y. Han In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells World J. Gastroenterol. 11 2005 5136 5141
25. C. Debbasch, M. De Saint Jean, P.J. Pisella, P. Rat, J.M. Warnet, and C. Baudouin Quaternary ammonium cytotoxicity in a human conjunctival cell line J. Fr. Ophtalmol. 22 1999 950 958
26. M. Uematsu, T. Kumagami, K. Shimoda, M. Kusano, M. Teshima, H. Sasaki, and T. Kitaoka Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity Cornea 29 2010 1296 1301
27. M. De Saint Jean, C. Debbasch, F. Brignole, J.M. Warnet, and C. Baudouin Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye Adv. Exp. Med. Biol. 506 2002 697 702
28. P. Aksungur, M. Demirbilek, E.B. Denkbas, J. Vandervoort, A. Ludwig, and N. Unlü Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies J. Control. Release 151 2011 286 294
29. O. Felt, P. Furrer, J.M. Mayer, B. Plazonnet, P. Buri, and R. Gurny Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention Int. J. Pharm. 180 1999 185 193
30. P. Calvo, J.L. Vila-Jato, and M.J. Alonso Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers Int. J. Pharm. 153 1997 41 50
31. C.T. Baldari, G. Macchia, A. Heguy, M. Melli, and J.L. Telford Cyclosporin A blocks calcium-dependent pathways of gene activation J. Biol. Chem. 266 1991 19103 19108
32. D. Harris, J. Liaw, and J. Robinson Ocular delivery of peptide and protein drugs Adv. Drug Deliv. Rev. 8 1992 331 339